News

Merck & Co has outlined its global plans after Merk’s merger with Schering-Plough. The new Merck will be a global health care leader aimed at providing innovative, distinctive

Scynexis has received a payment for meeting certain milestones in its multi-year research collaboration with Merial Limited, which began in 2005. Scynexis, focuses considerable medicinal chemistry, advanced biological

ISTA Pharmaceuticals (ISTA) reported that net revenue for the three and nine months ended September 30, 2009 was $32m and $76.4m respectively, an increase of 47% and 39%,

XOMA seeks to initiate an investigator sponsored phase 2 clinical trial of XOMA 052, its antibody to interleukin-1 beta (IL-1 beta), in Type 1 diabetes patients. The trial

Takeda Pharmaceuticals North America has established Takeda Pharmaceuticals Mexico, which will be headquartered in Mexico City. The company said that the expansion strengthens the company’s North American presence,

Abraxis Health, a fully-integrated personalised healthcare division of Abraxis BioScience, has dedicated its new manufacturing facility in Phoenix, Arizona. The biopharma manufacturing plant represents a $70m investment by

The US Food and Drug Administration (FDA) has granted orphan drug designation to GenVec’s TNFerade, for the treatment of pancreatic cancer. The company said that the FDA grants

Link Technologies has reported the commercialisation and launch of a range of unlocked-nucleic acid (UNA) monomers under license from RiboTask. Under the terms of the agreement Link is

Arch Chemicals has reported sales of $350.5m for the third quarter of 2009, compared to $367.9m for the same period of 2008. Higher pricing and the benefit from